Interview with CEO of Cinclus Pharma, Christer Ahlberg, after the listing.

Cinclus News Image Christer Trill 01

How does it feel after the listing?
"Fantastic. The listing means that we have secured funding for our upcoming phase III study for linaprazan glurate. We are now working hard to reach our goal of helping the most severe eGERD patients. A patient population that in the US and Europe amounts to approximately 10 million patients and a sales potential for Cinclus Pharma of over USD 1 billion per year."


Why is linaprazan glurate so good?
"Linaprazan glurate delivers close to 24 hours of acid control within 1-2 hours of the first dose. This leads to effective and rapid symptom relief and healing of close to 90% already within 4 weeks for the most difficult to treat patients, which is unique and superior to all competition."


What is the timeline?
"We are working to include the first patient in the Phase III study in 2025 and obtain results in 2026. If the efficacy data is in line with our expectations, we can apply to the FDA and EMA in 2028 or 2029 with the ambition of regulatory approval in 2029. Our intention is to out-license or enter other types of partnerships in all relevant markets worldwide."

Read more about linaprazan glurate.